An investigation that enrolled 92 cases with unresectable stage III pulmonary adenocarcinoma reported that patients with EGFR-mutant adenocarcinoma who underwent upfront EGFR-TKIs had significantly superior PFS and OS than those who underwent upfront concurrent chemoradiation. Here, EGFR is linked to adenocarcinoma.